Annexon, Inc.
ANNX · XNASCIK 1528115fmd_0986EWAQWFKS19JSMHAR55J6DVManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2019 to Sep 30, 2026, 31 periods
| Line item | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|
| Research and development | 25 | 49 | 100 | 113 | 114 | 119 | 185 |
| Total operating expenses | 33 | 63 | 131 | 146 | 144 | 154 | 216 |
| Operating income | (33) | (63) | (131) | (146) | (144) | (154) | (216) |
| Other non-operating income (expense) | 1 | 0 | – | – | – | – | – |
| Income before taxes | (37) | (63) | 130 | 142 | 134 | (138) | (207) |
| Income tax expense | 0 | – | – | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (37) | – | – | 142 | 134 | (138) | (207) |
| Net income | (37) | (63) | (130) | (142) | (134) | (138) | (207) |
| Net income to common shareholders | (38) | (70) | (130) | (142) | – | (138) | (209) |